6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The multitasking promyelocytic leukemia ( PML) protein was originally recognized as a tumor‐suppressive factor, but more recent evidence has implicated PML in tumor cell prosurvival actions and poor patient prognosis in specific cancer settings. Here, we report that inducible PMLIV expression inhibits cell proliferation as well as self‐renewal and impairs cell cycle progression of breast cancer cell lines in a reversible manner. Transcriptomic profiling identified a large number of PML‐deregulated genes associated with various cell processes. Among them, cell cycle‐ and division‐related genes and their cognitive regulators are highly ranked. In this study, we focused on previously unknown PML targets, namely the Forkhead transcription factors. PML suppresses the Forkhead box subclass M1 ( FOXM1) transcription factor at both the RNA and protein levels, along with many of its gene targets. We show that FOXM1 interacts with PMLIV primarily via its DNA‐binding domain and dynamically colocalizes in PML nuclear bodies. In parallel, PML modulates the activity of Forkhead box O3 ( FOXO3), a factor opposing certain FOXM1 activities, to promote cell survival and stress resistance. Thus, PMLIV affects the balance of FOXO3 and FOXM1 transcriptional programs by acting on discrete gene subsets to favor both growth inhibition and survival. Interestingly, PMLIV‐specific knockdown mimicked ectopic expression vis‐à‐vis loss of proliferative ability and self‐renewal, but also led to loss of survival ability as shown by increased apoptosis. We propose that divergent or similar effects on cell physiology may be elicited by high or low PMLIV levels dictated by other concurrent genetic or epigenetic cancer cell states that may additionally account for its disparate effects in various cancer types.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          FoxM1 is required for execution of the mitotic programme and chromosome stability.

          Transcriptional induction of cell-cycle regulatory proteins ensures proper timing of subsequent cell-cycle events. Here we show that the Forkhead transcription factor FoxM1 regulates expression of many G2-specific genes and is essential for chromosome stability. Loss of FoxM1 leads to pleiotropic cell-cycle defects, including a delay in G2, chromosome mis-segregation and frequent failure of cytokinesis. We show that transcriptional activation of cyclin B by FoxM1 is essential for timely mitotic entry, whereas CENP-F, another direct target of FoxM1 identified here, is essential for precise functioning of the mitotic spindle checkpoint. Thus, our data uncover a transcriptional cluster regulated by FoxM1 that is essential for proper mitotic progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Forkhead box proteins: tuning forks for transcriptional harmony.

            Forkhead box (FOX) proteins are multifaceted transcription factors that are responsible for fine-tuning the spatial and temporal expression of a broad range of genes both during development and in adult tissues. This function is engrained in their ability to integrate a multitude of cellular and environmental signals and to act with remarkable fidelity. Several key members of the FOXA, FOXC, FOXM, FOXO and FOXP subfamilies are strongly implicated in cancer, driving initiation, maintenance, progression and drug resistance. The functional complexities of FOX proteins are coming to light and have established these transcription factors as possible therapeutic targets and putative biomarkers for specific cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase.

              The Forkhead box m1 (Foxm1) gene is critical for G(1)/S transition and essential for mitotic progression. However, the transcriptional mechanisms downstream of FoxM1 that control these cell cycle events remain to be determined. Here, we show that both early-passage Foxm1(-)(/)(-) mouse embryonic fibroblasts (MEFs) and human osteosarcoma U2OS cells depleted of FoxM1 protein by small interfering RNA fail to grow in culture due to a mitotic block and accumulate nuclear levels of cyclin-dependent kinase inhibitor (CDKI) proteins p21(Cip1) and p27(Kip1). Using quantitative chromatin immunoprecipitation and expression assays, we show that FoxM1 is essential for transcription of the mitotic regulatory genes Cdc25B, Aurora B kinase, survivin, centromere protein A (CENPA), and CENPB. We also identify the mechanism by which FoxM1 deficiency causes elevated nuclear levels of the CDKI proteins p21(Cip1) and p27(Kip1). We provide evidence that FoxM1 is essential for transcription of Skp2 and Cks1, which are specificity subunits of the Skp1-Cullin 1-F-box (SCF) ubiquitin ligase complex that targets these CDKI proteins for degradation during the G(1)/S transition. Moreover, early-passage Foxm1(-)(/)(-) MEFs display premature senescence as evidenced by high expression of the senescence-associated beta-galactosidase, p19(ARF), and p16(INK4A) proteins. Taken together, these results demonstrate that FoxM1 regulates transcription of cell cycle genes critical for progression into S-phase and mitosis.
                Bookmark

                Author and article information

                Contributors
                papamath@imbb.forth.gr
                Journal
                Mol Oncol
                Mol Oncol
                10.1002/(ISSN)1878-0261
                MOL2
                Molecular Oncology
                John Wiley and Sons Inc. (Hoboken )
                1574-7891
                1878-0261
                16 May 2019
                June 2019
                : 13
                : 6 ( doiID: 10.1002/mol2.2019.13.issue-6 )
                : 1369-1387
                Affiliations
                [ 1 ] Department of Biology University of Crete Heraklion Greece
                [ 2 ] Institute of Molecular Biology and Biotechnology Foundation for Research and Technology‐Hellas (FORTH) Heraklion Greece
                [ 3 ] Department of Surgery and Cancer Imperial College London UK
                Author notes
                [*] [* ] Correspondence

                J. Papamatheakis, Department of Biology, University of Crete, N.Plastira 100, 70013 Heraklion, Crete, Greece

                Fax: +30‐2810‐391101

                Tel: +30‐2810‐391165

                E‐mail: papamath@ 123456imbb.forth.gr

                Article
                MOL212486
                10.1002/1878-0261.12486
                6547613
                30927552
                50889bf6-554c-4e16-aadc-139893714de2
                © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 13 September 2018
                : 17 January 2019
                : 29 March 2019
                Page count
                Figures: 5, Tables: 0, Pages: 19, Words: 10715
                Funding
                Funded by: State Scholarships Foundation
                Funded by: NIHR Imperial BRC
                Funded by: Thalis‐MIS380247‐MIREG (NSRF 2007–2013)
                Funded by: Medical Research Council
                Award ID: MR/N012097/1
                Funded by: Breast Cancer Now
                Award ID: 2012MayPR070
                Award ID: 2012NovPhD016
                Funded by: Fondation Sante (GLIOEVOL)
                Funded by: Imperial ECMC
                Funded by: Cancer Research UK Imperial Centre
                Funded by: CRUK
                Award ID: C37/A12011
                Award ID: C37/A18784
                Funded by: IMBB Internal Funding
                Funded by: General Secretariat for Research and Technology
                Award ID: 2014‐2020
                Award ID: 2015‐2017
                Funded by: European Molecular Biology Organization
                Funded by: European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation RESEARCH ‐ CREATE ‐ INNOVATE
                Award ID: T1EDK‐03186
                Award ID: MIS 5032840
                Award ID: DINNESMIN (A.K).
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                mol212486
                June 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:04.06.2019

                Oncology & Radiotherapy
                breast cancer,foxo3‐foxm1 network,growth arrest,pml,transcriptomics
                Oncology & Radiotherapy
                breast cancer, foxo3‐foxm1 network, growth arrest, pml, transcriptomics

                Comments

                Comment on this article